ATE540975T1 - Verbesserte faktor-viii-polypeptid-titer in zellkulturen - Google Patents

Verbesserte faktor-viii-polypeptid-titer in zellkulturen

Info

Publication number
ATE540975T1
ATE540975T1 AT08749930T AT08749930T ATE540975T1 AT E540975 T1 ATE540975 T1 AT E540975T1 AT 08749930 T AT08749930 T AT 08749930T AT 08749930 T AT08749930 T AT 08749930T AT E540975 T1 ATE540975 T1 AT E540975T1
Authority
AT
Austria
Prior art keywords
factor viii
viii polypeptide
cell cultures
improved factor
polypeptide titer
Prior art date
Application number
AT08749930T
Other languages
English (en)
Inventor
Laust Johnsen
Ida Hilden
Gert Bolt
Thomas Steenstrup
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38519867&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE540975(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Application granted granted Critical
Publication of ATE540975T1 publication Critical patent/ATE540975T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT08749930T 2007-05-04 2008-04-30 Verbesserte faktor-viii-polypeptid-titer in zellkulturen ATE540975T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07107477A EP1988101A1 (de) 2007-05-04 2007-05-04 Verbesserung von Faktor-VIII-Polypeptid-Titern in Zellkulturen
PCT/EP2008/055349 WO2008135501A1 (en) 2007-05-04 2008-04-30 Improvement of factor viii polypeptide titers in cell cultures

Publications (1)

Publication Number Publication Date
ATE540975T1 true ATE540975T1 (de) 2012-01-15

Family

ID=38519867

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08749930T ATE540975T1 (de) 2007-05-04 2008-04-30 Verbesserte faktor-viii-polypeptid-titer in zellkulturen

Country Status (14)

Country Link
US (1) US9982033B2 (de)
EP (2) EP1988101A1 (de)
JP (1) JP5506664B2 (de)
KR (1) KR101594805B1 (de)
CN (1) CN101675073B (de)
AT (1) ATE540975T1 (de)
AU (1) AU2008248627B2 (de)
BR (1) BRPI0811177A2 (de)
CA (1) CA2684951A1 (de)
ES (1) ES2379846T3 (de)
MX (1) MX2009011805A (de)
PL (1) PL2144929T3 (de)
RU (1) RU2477318C2 (de)
WO (1) WO2008135501A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI456062B (zh) 2006-09-13 2014-10-11 Abbvie Inc 細胞培養改良
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
MX2011004201A (es) 2008-10-20 2011-05-24 Abbott Lab Desactivacion viral durante purificacion de anticuerpos.
AU2009347206C1 (en) 2008-10-20 2016-12-08 Abbvie Inc. Isolation and purification of antibodies using Protein A affinity chromatography
CN107190034A (zh) 2010-10-05 2017-09-22 诺沃—诺迪斯克保健股份有限公司 生产蛋白质的方法
EP2702077A2 (de) 2011-04-27 2014-03-05 AbbVie Inc. Verfahren zur steuerung des galactosylierungsprofil von rekombinant exprimierten proteinen
WO2013075926A1 (en) 2011-11-21 2013-05-30 Novo Nordisk A/S Method for production of factor viii
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
KR101395736B1 (ko) * 2012-07-10 2014-05-16 아주대학교산학협력단 인간 혈액응고인자 ⅷ 도메인 특이적 항체 및 이의 제조방법
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
HK1211981A1 (en) 2012-09-02 2016-06-03 Abbvie Inc. Methods to control protein heterogeneity
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
EP3132050A1 (de) * 2014-04-16 2017-02-22 CMC Biologics A/S Füll- und abzugsfermentationsverfahren mit hoher zelldichte
US10238718B2 (en) 2014-08-04 2019-03-26 Csl Limited Factor VIII formulation
ES2772933T3 (es) 2015-03-06 2020-07-08 CSL Behring Lengnau AG Factor de von Willebrand modificado que tiene una semivida mejorada
CN114072420B (zh) 2019-07-04 2024-06-11 康诺贝林伦瑙有限公司 用于增加凝血因子viii的体外稳定性的截短的血管性血友病因子(vwf)
JP7680442B2 (ja) 2019-11-11 2025-05-20 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 第ｖｉｉｉ因子に対する寛容を誘導するためのポリペプチド
KR20250110226A (ko) 2022-11-23 2025-07-18 에프. 호프만-라 로슈 아게 재조합 단백질 발현을 증가시키는 방법

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672502A (en) 1985-06-28 1997-09-30 Celltech Therapeutics Limited Animal cell culture
DE3785102T2 (de) 1986-01-03 1993-07-22 Genetics Inst Verfahren zur herstellung von faktor-viii:c-typ-proteinen.
US5250421A (en) * 1986-01-03 1993-10-05 Genetics Institute, Inc. Method for producing factor VIII:C-type proteins
EP0254076B1 (de) * 1986-07-11 1991-05-08 Miles Inc. Herstellung von rekombinantem Protein
CA1331157C (en) 1987-04-06 1994-08-02 Randal J. Kaufman Method for producing factor viii:c-type proteins
WO1990002175A1 (en) 1988-08-16 1990-03-08 Novo Nordisk A/S A method of producing polypeptides by culturing eukaryotic cells in the presence of protease inhibitors
US5952198A (en) * 1995-05-04 1999-09-14 Bayer Corporation Production of recombinant Factor VIII in the presence of liposome-like substances of mixed composition
US5679549A (en) * 1995-05-04 1997-10-21 Bayer Corporation Production of recombinant factor VIII in the presence of liposome-like substances of mixed composition
US5851800A (en) 1996-05-14 1998-12-22 Pharmacia & Upjohn Ab Process for producing a protein
US6458563B1 (en) * 1996-06-26 2002-10-01 Emory University Modified factor VIII
US6338964B1 (en) 1999-05-07 2002-01-15 Bayer Corporation Process and medium for mammalian cell culture under low dissolved carbon dioxide concentration
AT409379B (de) * 1999-06-02 2002-07-25 Baxter Ag Medium zur protein- und serumfreien kultivierung von zellen
EP1359936B1 (de) * 2001-02-05 2008-02-20 Novo Nordisk Health Care AG Kombinierte verwendung von faktor vii polypeptiden und faktor viii polypeptiden
US20040229793A1 (en) * 2003-02-05 2004-11-18 Balasubramanian Sathyamangalam V. Compositions and methods for less immunogenic protein formulations
US7351688B2 (en) * 2003-02-05 2008-04-01 The Research Foundation Of State University Of New York Compositions and methods for less immunogenic protein formulations
EP1707634A1 (de) * 2005-03-29 2006-10-04 Octapharma AG Verfahren zur Isolierung von rekombinant hergestellten Proteinen

Also Published As

Publication number Publication date
EP2144929A1 (de) 2010-01-20
JP2010525829A (ja) 2010-07-29
RU2477318C2 (ru) 2013-03-10
US20100120094A1 (en) 2010-05-13
ES2379846T3 (es) 2012-05-04
AU2008248627B2 (en) 2013-06-06
WO2008135501A1 (en) 2008-11-13
CN101675073A (zh) 2010-03-17
RU2009143635A (ru) 2011-06-10
CA2684951A1 (en) 2008-11-13
EP2144929B1 (de) 2012-01-11
US9982033B2 (en) 2018-05-29
BRPI0811177A2 (pt) 2014-10-29
JP5506664B2 (ja) 2014-05-28
CN101675073B (zh) 2013-12-04
KR20100016430A (ko) 2010-02-12
PL2144929T3 (pl) 2012-06-29
KR101594805B1 (ko) 2016-02-17
AU2008248627A1 (en) 2008-11-13
MX2009011805A (es) 2009-11-13
EP1988101A1 (de) 2008-11-05

Similar Documents

Publication Publication Date Title
ATE540975T1 (de) Verbesserte faktor-viii-polypeptid-titer in zellkulturen
IL252607A0 (en) Culture media, cell cultures and methods of culturing pluripotent stem cells in an undifferentiated state
CL2011001926A1 (es) Biorreactor para el cultivo de celulas de mamiferos donde dicho biorreactor posee un volumen de al menos 4000 l y al menos un impulsor superior y al menos un impulsor de fondo, donde el impulsor superior es un impulsor de hidroplano; metodo de cultivo; sistema de bioreactor.
NZ630551A (en) Methods and means for the production of ig-like molecules
MY181513A (en) Cell culture compositions and methods for polypeptide production
MX2013014937A (es) Cultivo de celulas de mamifero.
WO2010048417A3 (en) Perfusion bioreactors, cell culture systems, and methods for production of cells and cell-derived products
NZ598677A (en) Production of proteins in glutamine-free cell culture media
IN2012DN05207A (de)
EP2438161A4 (de) Verfahren zur herstellung induzierter pluripotenter stammzellen und verfahren zu ihrer kultivierung
EP4148121A3 (de) Zellgesteuerte perfusion in kontinuierlicher kultur
DK2171034T3 (da) Metode til fremstilling af en biopolymer i en kontinuerlig perfusionsgæringsproces
WO2008055190A3 (en) Closed photobioreactor system for production of ethanol
WO2010096588A3 (en) Cell culture media containing combinations of proteins
BRPI0922572A2 (pt) método para cultivar células pluripotentes, cultura de células de mamífero pluripotentes, meio de cultura de célula, célula animal pluripotente isolada, e, método para aumentar a pluripotência de uma célula de mamífero.
ECSP11010873A (es) Método de cultivo continuo, recolección y extracción de un microorganismo fotosíntetico
EA200900286A1 (ru) Модификация бактерий для получения этанола
EP2582792A4 (de) Kardiomyozytenmedium mit dialysiertem serum
WO2010020876A3 (en) Cell culture method to form aggregates
EA201491785A1 (ru) Способ ферментации
ATE375385T1 (de) Verwendung eines serumfreien zellkulturmediums zur produktion von il-18bp in säugerzellen
ATE552345T1 (de) Verfahren zur herstellung von fermentationsprodukten
WO2014049382A3 (en) Ethylenediamine fermentative production by a recombinant microorganism
ATE550944T1 (de) Pilzstämme und ein verfahren zur herstellung eines insektizids von diesen stämmen
EA200900984A1 (ru) Улучшение клеточного роста